Global Dry Eye Syndrome Market Growth 2023-2029

Global Dry Eye Syndrome Market Growth 2023-2029

Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment.
In this report, we mainly study the drugs and eye drops for dry eye.
LPI (LP Information)' newest research report, the “Dry Eye Syndrome Industry Forecast” looks at past sales and reviews total world Dry Eye Syndrome sales in 2022, providing a comprehensive analysis by region and market sector of projected Dry Eye Syndrome sales for 2023 through 2029. With Dry Eye Syndrome sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dry Eye Syndrome industry.
This Insight Report provides a comprehensive analysis of the global Dry Eye Syndrome landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dry Eye Syndrome portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Dry Eye Syndrome market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dry Eye Syndrome and breaks down the forecast by type, by distribution channel, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dry Eye Syndrome.
The global Dry Eye Syndrome market size is projected to grow from US$ 5267.9 million in 2022 to US$ 7250 million in 2029; it is expected to grow at a CAGR of 7250 from 2023 to 2029.
Global Dry Eye Syndrome key players include Allergan, Alcon, Novartis, Santen Pharma, Johnson & Johnson, etc. Global top five manufacturers hold a share over 60%.
North America is the largest market, with a share over 55%, followed by Europe and Asia-Pacific, both have a share over 35 percent.
In terms of product, Anti-inflammatory Drugs is the largest segment, with a share over 50%. And in terms of application, the largest application is Hospital, followed by Retail Pharmacy.
This report presents a comprehensive overview, market shares, and growth opportunities of Dry Eye Syndrome market by product type, distribution channel, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Artificial Tears
Anti-inflammatory Drugs
Others
Segmentation by distribution channel
Hospital
Retail Pharmacy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan
Alcon
Novartis
Santen Pharma
Johnson & Johnson
Bausch & Lomb
Thea pharmaceuticals
URSAPHARM
SIMILASAN
Akorn
United Laboratories
Sun Pharmaceutical
Jianfeng Group

Key Questions Addressed in this Report
What is the 10-year outlook for the global Dry Eye Syndrome market?
What factors are driving Dry Eye Syndrome market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dry Eye Syndrome market opportunities vary by end market size?
How does Dry Eye Syndrome break out type, distribution channel?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.